FDA approves breakthrough drug to treat advanced pancreatic cancer

(WASHINGTON) — The Food and Drug Administration approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer.

The drug, called daraxonrasib, will be sold under the brand name Rasonque. The daily pill targets multiple forms of a protein called RAS, which is a main driver of tumor growth.

This is a developing story. Please check back for updates.